









Markets
/
Stocks
/
nasdaq-pavm
/

PAVmed Inc

PAVM

10.800USD

+0.220+2.08%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

8.30MMarket Cap

LossP/E TTM



PAVmed Inc

10.800

+0.220+2.08%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of PAVmed Inc

Currency: USD Updated: 2026-02-06

Key Insights

PAVmed Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 122 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 315.00.In the medium term, the stock price is expected to remain stable.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PAVmed Inc's Score

Industry at a Glance

Industry Ranking

122 / 205

Overall Ranking

318 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

PAVmed Inc Highlights

StrengthsRisks

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 694.43% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.00M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -3.57, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 96.72K shares, increasing 26.46% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 11.41K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.27.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

315.000

Target Price

+2877.32%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of PAVmed Inc is 5.18, ranking 201 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 5.00K, representing a year-over-year decrease of 99.50%, while its net profit experienced a year-over-year decrease of 109.84%.

Score

Industry at a Glance

Previous score

5.18

Change



Financials

6.68

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

2.76

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

PAVmed Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of PAVmed Inc is 6.76, ranking 151 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -3.57, which is -127.36% below the recent high of 0.98 and -3247.19% above the recent low of -119.51.

Score

Industry at a Glance

Previous score

6.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 122/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of PAVmed Inc is 8.00, ranking 60 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 12.00, with a high of 20.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

315.000

Target Price

+2877.32%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

PAVmed Inc

PAVM

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of PAVmed Inc is 7.08, ranking 53 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 24.12 and the support level at 1.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.08

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.553

Buy

RSI(14)

58.890

Neutral

STOCH(KDJ)(9,3,3)

58.540

Buy

ATR(14)

3.055

High Vlolatility

CCI(14)

39.650

Neutral

Williams %R

78.997

Sell

TRIX(12,20)

0.522

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

10.112

Buy

MA10

9.206

Buy

MA20

8.934

Buy

MA50

9.045

Buy

MA100

9.502

Buy

MA200

5.042

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of PAVmed Inc is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 9.71%, representing a quarter-over-quarter increase of 14.22%. The largest institutional shareholder is The Vanguard, holding a total of 11.41K shares, representing 1.15% of shares outstanding, with 140.27% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Tasso Partners, LLC

85.81K

Sargent Investment Group, LLC

33.54K

First Manhattan Co. LLC

23.80K

Dubreville (Anthony Michael)

20.21K

The Vanguard Group, Inc.

Star Investors

6.95K

+155.74%

Pavilion Venture Partners, L.L.C.

9.90K

Aklog (Lishan)

7.62K

Glennon (Michael J)

7.56K

-2.15%

White (Debra Jayne)

7.17K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of PAVmed Inc is 1.16, ranking 198 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.90. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. PAVmed Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.